IRIS
DEL PRINCIPE, MARIA ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 35.651
AS - Asia 6.348
EU - Europa 5.571
SA - Sud America 959
Continente sconosciuto - Info sul continente non disponibili 862
AF - Africa 94
OC - Oceania 31
Totale 49.516
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 35.379
SG - Singapore 2.733
IT - Italia 1.663
CN - Cina 1.184
DE - Germania 821
RU - Federazione Russa 774
BR - Brasile 773
HK - Hong Kong 666
VN - Vietnam 506
IE - Irlanda 490
UA - Ucraina 443
BD - Bangladesh 407
GB - Regno Unito 301
FR - Francia 273
JP - Giappone 200
KR - Corea 190
FI - Finlandia 187
CA - Canada 170
NL - Olanda 156
SE - Svezia 150
IN - India 114
PL - Polonia 78
AR - Argentina 61
AT - Austria 56
MX - Messico 52
ID - Indonesia 48
ES - Italia 47
TR - Turchia 36
CO - Colombia 33
BE - Belgio 31
IQ - Iraq 31
PH - Filippine 31
ZA - Sudafrica 30
AU - Australia 28
PK - Pakistan 25
IR - Iran 23
EC - Ecuador 21
TH - Thailandia 21
VE - Venezuela 21
UZ - Uzbekistan 19
SA - Arabia Saudita 17
CZ - Repubblica Ceca 15
CL - Cile 14
MY - Malesia 14
PY - Paraguay 14
DZ - Algeria 12
EG - Egitto 12
IL - Israele 12
MA - Marocco 12
CH - Svizzera 11
LT - Lituania 11
NP - Nepal 11
PE - Perù 11
LB - Libano 9
AE - Emirati Arabi Uniti 8
JM - Giamaica 8
TW - Taiwan 8
UY - Uruguay 8
DO - Repubblica Dominicana 7
EU - Europa 7
HR - Croazia 7
TN - Tunisia 7
AL - Albania 6
CR - Costa Rica 6
GR - Grecia 6
HN - Honduras 6
KE - Kenya 6
RO - Romania 6
RS - Serbia 6
SN - Senegal 6
A2 - ???statistics.table.value.countryCode.A2??? 5
AZ - Azerbaigian 5
GT - Guatemala 5
SK - Slovacchia (Repubblica Slovacca) 5
BY - Bielorussia 4
JO - Giordania 4
KZ - Kazakistan 4
LI - Liechtenstein 4
NO - Norvegia 4
PT - Portogallo 4
BB - Barbados 3
HU - Ungheria 3
NI - Nicaragua 3
OM - Oman 3
TT - Trinidad e Tobago 3
BO - Bolivia 2
ET - Etiopia 2
GE - Georgia 2
KG - Kirghizistan 2
KH - Cambogia 2
KW - Kuwait 2
MN - Mongolia 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
PS - Palestinian Territory 2
QA - Qatar 2
AG - Antigua e Barbuda 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
Totale 48.641
Salva come PNG Salva come JPEG
Città #
Woodbridge 9.113
Wilmington 8.876
Houston 5.164
Singapore 1.523
Fairfield 1.321
Ashburn 1.044
Chandler 975
San Jose 833
Ann Arbor 732
Hong Kong 645
Seattle 544
Beijing 491
Cambridge 464
Rome 428
Dublin 409
New York 379
Jacksonville 356
Santa Clara 303
Dearborn 288
Medford 288
Council Bluffs 263
Los Angeles 225
The Dalles 220
Dallas 214
Tokyo 181
Ho Chi Minh City 159
Lawrence 136
Buffalo 126
Moscow 117
Milan 115
Lauterbourg 108
Hanoi 106
Boardman 104
Zhengzhou 100
San Diego 74
São Paulo 74
Chicago 57
Helsinki 57
Munich 56
Mülheim 52
Nuremberg 50
Warsaw 50
Brooklyn 49
Montreal 49
Menlo Park 47
Bologna 44
Orem 44
Toronto 44
Creede 43
Frankfurt am Main 42
Atlanta 41
London 41
North Bergen 39
Phoenix 35
Redondo Beach 35
Engelhard 33
Jakarta 33
Lappeenranta 32
Seoul 32
Da Nang 30
Naples 29
Shanghai 29
Brussels 27
Denver 27
Redwood City 26
Turin 26
Chennai 25
Columbus 25
Guangzhou 25
Boston 23
Hefei 22
Rio de Janeiro 22
Stockholm 22
Vienna 22
Bari 21
Florence 21
Palo Alto 21
Amsterdam 20
Belo Horizonte 20
Norwalk 20
Haiphong 18
Johannesburg 18
Mexico City 18
Poplar 18
San Francisco 17
University Park 17
Verona 17
Center 16
Turku 16
Campinas 14
Las Vegas 14
Nanjing 14
Shenzhen 14
Baghdad 13
Charlotte 13
Falls Church 13
Kraków 13
Kunming 13
Manchester 13
Quito 13
Totale 38.308
Salva come PNG Salva come JPEG
Nome #
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 639
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 542
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 514
Clinical significance of CD38 expression in chronic lymphocytic leukemia 494
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 489
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 484
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 474
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 473
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 471
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 452
NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma 452
Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study 448
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients 446
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia 446
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. 445
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage 444
A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia 443
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy 440
Advances in the treatment of elderly and frail patients with acute myeloid leukemia 439
Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia 435
Lack of efficacy of imiquimod in patients with basal cell carcinoma previously treated with rituximab for B cell lymphoma: two case reports 433
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia 431
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 431
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia 425
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation 422
Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia 421
ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations 421
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. 418
Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23(+)/MLL+ translocation in leukaemia 418
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 417
Femoral catheters: safety and efficacy in peripheral blood stem cell collection 417
Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes 416
The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells 413
Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells 412
Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey 410
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia 410
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications 406
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study 404
Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. 404
A cluster of Geotrichum clavatum (Saprochaete clavata) infection in haematological patients: a first Italian report and review of literature 404
Monitoring of minimal residual disease in acute myeloid leukemia 403
Circulating regulatory T cells in clinical monoclonal B-cell lymphocytosis. 403
Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome 403
The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia 402
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow 401
High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma 401
Treatment of Acute Myeloid Leukemia with 20-30% Bone Marrow Blasts 395
Treatment of low-blast count AML using hypomethylating agents 394
DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE 392
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy 388
Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia 386
Minimal Residual Disease as Biomarker for Optimal Biologic Dosing of ARA-C in Patients with Acute Myeloid Leukemia 386
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 379
CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias 378
Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia 377
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features 375
Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia 375
Extensive toxic epidermal necrolysis following brentuximab vedotin administration 373
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. 370
Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia 368
Longitudinal detection of DNMT3AR882Htranscripts in patients with acute myeloid leukemia 368
Successful treatment of disseminated fusariosis with high dose liposomal amphotericin-B in a patient with acute lymphoblastic leukemia [4] 365
Apoptosis and immaturity in acute myeloid leukemia 364
Posaconazole oral suspension primary prophylaxis in acute leukemia and allogeneic stem cell transplant patients: can it be used without measurement of plasma concentration? 364
Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. 363
Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia 363
Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia 362
Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia 361
Thrombosis in adult patients with acute leukemia 359
CD69 is independently prognostic in chronic lymphocytic leukemia: acomprehensive clinical and biological profiling study 358
Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia 356
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia 350
Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia. 349
Circulating regulatory T cells in "clinical" monoclonal B-cell lymphocytosis 349
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia 349
Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy 346
Minimal residual disease detection in pediatric acute myeloid leukemia: does flow cytometry score a point over molecular biology? 346
Risk allocation of adults patients with non-M3 acute myeloid leukemia 344
Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes 339
In vitro elimination of EGFR-overexpressing cancer cells by CD32A chimeric receptor T cells in combination with cetuximab or panitumumab 339
Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient 332
Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. 332
The emerging role of measurable residual disease detection in AML in morphologic remission 329
Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the campus all network 327
Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling 323
FCγ chimeric receptor-engineered T cells: Methodology, advantages, limitations, and clinical relevance 322
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 314
Fludarabine, Cytarabine and Gentuzumab Ozogamicin (FLA-GO) as Salvage Therapy and Bridge to Transplant in Adult Relapsed Acute Myeloid Leukemia (AML) Patients 310
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study 305
Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse 300
Real-life analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study 286
Gemtuzumab ozogamicin in combination with intensive chemotherapy for relapsed/refractory acute myeloid leukemia 283
Case report: A Saprochaete clavata (Magnusiomyces clavatus) severe infection effectively treated with granulocyte transfusion in a young patient with myeloid sarcoma 261
Clinical relevance of an objective - limit of detection - limit of quantification - based flow cytometry approach for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial 247
An evaluation of enasidenib for the treatment of acute myeloid leukemia 246
ACUTE LEUKEMIA AND LATENT TUBERCULOSIS INFECTION IN ITALY: QUANTIFERON-TB TEST SCREENING IN A LOW TUBERCULOSIS INCIDENCE COUNTRY 228
Fungal infections of the central nervous system and paranasal sinuses in onco-haematologic patients. Epidemiological study reporting the diagnostic-therapeutic approach and outcome in 89 cases 224
Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness 222
Rhodotorula infection in haematological patient: Risk factors and outcome 219
Central nervous system fungal infections in allogeneic stem cell transplantation. Outcome of 24 recent cases and literature review 214
Totale 38.270
Salva come PNG Salva come JPEG
Categoria #
all - tutte 141.687
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 141.687
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.610 0 172 46 48 33 171 100 113 139 165 92 531
2022/20232.609 286 230 230 261 157 472 288 163 285 46 134 57
2023/20241.219 104 52 135 35 99 331 57 83 43 31 35 214
2024/20254.639 181 890 531 245 85 285 403 208 485 473 391 462
2025/20269.032 860 419 990 689 858 335 1.017 1.068 1.025 731 513 527
2026/2027654 470 184 0 0 0 0 0 0 0 0 0 0
Totale 49.516